Investor Overview

NASDAQ: XBIT0.24.19Data provided by Nasdaq.
Minimum 15 minutes delayed.

XBiotech is building on a foundation of remarkable new therapies, innovative approaches to commercialization and a commitment to realizing treatments for unmet medical needs worldwide.

Recent News
DateTitle 
09/21/17XBiotech to Present at Cantor Fitzgerald’s Global Healthcare ConferencePrinter Friendly Version
09/20/17XBiotech Announces Agreement with Cedars-Sinai Medical Center to Evaluate MABp1 in Combination with OnivydeⓇ and 5-fluorouracil/folinic acid for the Treatment of Pancreatic CancerPrinter Friendly Version
09/07/17XBiotech Announces Presentation of Phase 2 Study Data Evaluating MABp1 for the Treatment of Hidradenitis SuppurativaPrinter Friendly Version

Read more »

Upcoming Events
DateTitle
09/27/17
2:50 p.m. ET
XBiotech Inc at the Cantor Fitzgerald’s Global Healthcare Conference
LocationInterContinental New York Barclay Hotel

Read more »